Quantcast
Home > Quotes > ALPN

Alpine Immune Sciences, Inc. Common Stock (ALPN) Quote & Summary Data

ALPN 
$6.39
*  
0.11
1.69%
Get ALPN Alerts
*Delayed - data as of Sep. 25, 2018  -  Find a broker to begin trading ALPN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 6.50 / $ 6.36
Share Volume
12,869
50 Day Avg. Daily Volume
17,666
Previous Close
$ 6.50
52 Week High / Low
$ 12.8689 / $ 5.28
Market Cap
88,506,369
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
12,869
50 Day Avg. Daily Volume:
17,666

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.10

Trading Range

The current last sale of $6.39 is 21.02% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 6.50 $ 12.8689
 Low: $ 6.36 $ 5.28

Company Description (as filed with the SEC)

Our company is focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases. Our proprietary scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins. In our pre-clinical studies, our scientific platform has proven capable of identifying novel molecules, including single domains capable of modulating multiple targets. These molecules have demonstrated efficacy in in vitro and in vivo mouse models. We believe therapeutics generated by our scientific platform have the potential to provide benefit in a broad range of immune system disorders. We have chosen to focus our initial efforts in select areas with unmet medical needs in oncology and inflammatory/autoimmune diseases.  ... More ...  


Risk Grade

Where does ALPN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 6.49
Open Date:
Sep. 25, 2018
Close Price:
$ 6.50
Close Date:
Sep. 25, 2018

Consensus Recommendation

Analyst Info